Hepatitis B Virus (HBV)

Category: Bronchoscopy

Rapid Mucosal Absorption of Topical Lidocaine During Bronchoscopy in the Presence of Oral Candidiasis: Conclusion

Rapid Mucosal Absorption of Topical Lidocaine During Bronchoscopy in the Presence of Oral Candidiasis: Conclusion

These values are total concentrations, both bound and free lidocaine, and give no information about free fraction, which we did not investigate. The major plasma protein which binds lidocaine and several other basic drugs, alpha!-acid glycoprotein is an acute-phase protein that is elevated in certain situations such as stress, neoplastic disease, acute and chronic inflammatory […]

Rapid Mucosal Absorption of Topical Lidocaine During Bronchoscopy in the Presence of Oral Candidiasis: Discussion

This case is remarkable in that lidocaine solution and jelly applied to the oropharynx and bronchial tree were rapidly and extensively absorbed attaining a peak plasma concentration of 7.1 μg/ml within 0.67 hour of the start of drug administration (Fig 1). Furthermore, for four hours after the procedure, the plasma levels remained greater than 1.5 […]

Figure 1. Plasma lidocaine concentrations before, during, and after bronchoscopy. Arrows mark beginning and end of the bronchoscopy procedure. Bar graphs show doses and times of administration of lidocaine solution by atomizer (hatched bar), lidocaine jelly (solid bar), and lidocaine solution through the bronchoscope (open bar).

Rapid Mucosal Absorption of Topical Lidocaine During Bronchoscopy in the Presence of Oral Candidiasis

Systemic absorption of lidocaine following its topical application during diagnostic procedures can produce central nervous system or cardiac toxicity. Objective signs of toxicity are more likely at plasma concentrations above 6 μml, which are only rarely reported during bronchoscopy. It is useful, therefore, to identify patient populations at risk for developing these undesired effects due […]

Tags